1. ACCEPT: A PHASE IB/II COMBINATION OF ACALABRUTINIB WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R‐CHOP) FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (12th June 2019) Authors: Cummin, T.E.; Caddy, J.; Mercer, K.; Maishman, T.; Schuh, A.; Lopez Pascua, L.; Collins, G.; McMillan, A.; Ardeshna, K.; Galanopoulous, A.; Burton, C.; Barrans, S.; Griffiths, G.; Johnson, P.; Davies, A.J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH‐DOSE THERAPY. (12th June 2019) Authors: Davies, A.J.; Tansley Hancock, O.; Cummin, T.; Caddy, J.; Stanton, L.; Burton, C.; Barrans, S.; Coleman, A.; Osborne, W.; McKay, P.; Griffiths, G.; Johnson, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DIFFERENTIAL EFFICACY OF BORTEZOMIB IN SUBTYPES OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBL): a PROSPECTIVE RANDOMISED STUDY STRATIFIED BY TRANSCRIPTOME PROFILING: REMODL‐B. (June 2017) Authors: Davies, A.J.; Barrans, S.; Maishman, T.; Cummin, T.E.; Bentley, M.; Mamot, C.; Novak, U.; Caddy, J.; Hamid, D.; Kazmi‐Stokes, S.H.; Mcmillan, A.; Fields, P.A.; Pocock, C.; Kruger, A.; Collins, G.; Sha, C.; Clipson, A.; Wang, M.; Tooze, R.M.; Care, M.A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗